Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04720313 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NXC-201 (formerly HBI0101) Multiple Myeloma

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 14, 2025 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jan 2025 to Jan 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Jan 2026 to Jan 2027
    • Site details revised
    v4
  2. Enrollment target: 48 to 160
    • Study description shortened, about 44 words
    v3
  3. Primary completion date: Jan 2023 to Jan 2025v2 Show 4 more changesShow less
    • Interventions: CART BCMA (Drug) to NXC-201 (formerly HBI0101) (Drug)
    • Study description expanded, about 6 words
    • Collaborators expanded, about 2 words
    • Study title expanded, about 2 words
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
It is a phase one study with dose escalation and safety CART in BCMA- Expressing Multiple Myeloma and AL amyloidosis Patients
Trial Details
NCT Number NCT04720313
Lead Sponsor Hadassah Medical Organization
Collaborators: Nexcella Inc.
Conditions
(from sponsor)		 Dose Escalation and Safety
Enrollment 160 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov